Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) have been given an average recommendation of "Hold" by the five analysts that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $5.60.
Separately, Weiss Ratings restated a "sell (e+)" rating on shares of Cytek Biosciences in a research report on Saturday, September 27th.
Read Our Latest Report on CTKB
Cytek Biosciences Stock Performance
NASDAQ:CTKB traded up $0.32 during midday trading on Friday, reaching $3.97. 1,306,885 shares of the stock traded hands, compared to its average volume of 1,002,647. The company has a fifty day moving average of $3.88 and a 200 day moving average of $3.58. The stock has a market capitalization of $505.08 million, a P/E ratio of -79.40 and a beta of 1.32. Cytek Biosciences has a 12 month low of $2.37 and a 12 month high of $7.63.
Hedge Funds Weigh In On Cytek Biosciences
Several institutional investors and hedge funds have recently added to or reduced their stakes in CTKB. Federated Hermes Inc. grew its stake in shares of Cytek Biosciences by 150.9% during the second quarter. Federated Hermes Inc. now owns 7,221 shares of the company's stock worth $25,000 after acquiring an additional 4,343 shares during the last quarter. Brooklyn Investment Group grew its stake in shares of Cytek Biosciences by 992,200.0% during the first quarter. Brooklyn Investment Group now owns 9,923 shares of the company's stock worth $40,000 after acquiring an additional 9,922 shares during the last quarter. US Bancorp DE grew its stake in shares of Cytek Biosciences by 9,698.2% during the first quarter. US Bancorp DE now owns 10,680 shares of the company's stock worth $43,000 after acquiring an additional 10,571 shares during the last quarter. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Cytek Biosciences during the second quarter worth about $42,000. Finally, Captrust Financial Advisors purchased a new stake in shares of Cytek Biosciences during the second quarter worth about $43,000. Hedge funds and other institutional investors own 69.46% of the company's stock.
About Cytek Biosciences
(
Get Free Report)
Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cytek Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytek Biosciences wasn't on the list.
While Cytek Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.